Purchase this article with an account.
Vikas Khetan, Subramanian Krishnakumar, Sreelakshmi Kummamuri, Anita Ramesh; Anterior chamber seeding in retinoblastoma: is it an indication for adjuvant chemotherapy. A long term follow up study.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3678.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report the outcome of 34 patients of retinoblastoma with anterior chamber invasion with a long term follow up.
This was a retrospective review of 307 enucleations over a period of 6 years (from July 2007 to June 2012), having IIRC E retinoblastoma. 34 patients with at least 6 months of follow up who were found to have anterior chamber invasion on histopathological examination of enucleated eye were included for the study. Eyes showing anterior chamber seeding along with other high risk features were administered adjuvant chemotherapy (Group 1). Eyes with only anterior chamber seeds and no other high risk features were not given adjuvant chemotherapy (Group 2).
In the 6 year period, 307 enucleations were performed. 38.76% (119) of these eyes had high risk features. 34 of the 307 eyes showed anterior chamber seeds on histopathological examination and were included in the study. Mean follow up of these eyes was 38.7 months with a range of 6 months to 84 months. Only 2 cases had follow up less than 1 year. Of these 34 eyes, Group 1 had 20 (58.82%) eyes.This group had a mean follow up of 39.15 months. 14 (41.17%) eyes were in Group 2. Mean follow up of these patients was 38.07 months. During the entire period none of the patients in both groups developed metastasis.
Anterior chamber invasion alone, in the absence of other histopathological risk factors, does not warrant adjuvant chemotherapy. This retrospective study reveals a 0% rate of metastasis when isolated anterior chamber seeding was not treated with adjuvant chemotherapy. In cases with AC invasion that receive adjuvant chemotherapy, chemotherapy was given because of other high risk features.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only